Sara Pellegrino | Senior Vice President, Investor & Public Relations & Corporate Communications |
Fred Vogt | Interim President & Chief Executive Officer |
Igor Bilinsky | Chief Operating Officer |
Jim Ziegler | Executive Vice President, Commercial |
Friedrich Finckenstein | Chief Medical Officer |
Jean-Marc Bellemin | Chief Financial Officer |
Peter Lawson | Barclays |
Dennis Ding | Jefferies |
Tyler Van Buren | Cowen |
Reni Benjamin | JMP Securities |
Mark Breidenbach | Oppenheimer |
Mara Goldstein | Mizuho |
Ben Burnett | Stifel |
Colleen Kusy | Baird |
Joe Catanzaro | Piper Sandler |
Welcome to the Iovance Biotherapeutics Second Quarter and First Half 2022 Financial Results and Corporate Update Conference Call. My name is Andrew, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded.